Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.79 +0.3%	$10.06	$6.02 ▼ $11.31	$1.84B	1.04	3.04 million shs	2.91 million shs
CABA Cabaletta Bio	$1.51 +1.3%	$1.71	$0.99 ▼ $8.77	$76.62M	2.7	1.67 million shs	1.83 million shs
CBMG Cellular Biomedicine Group		$19.68	$11.48 ▼ $19.75	$384.69M	1.35	129,776 shs	8,375 shs
GRTS Gritstone bio		$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	61.02 million shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-2.07%	-2.23%	-20.65%	+35.39%	+34.36%
CABA Cabaletta Bio	-7.22%	-1.97%	-39.92%	+43.27%	-78.87%
CBMG Cellular Biomedicine Group	0.00%	0.00%	0.00%	0.00%	0.00%
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	-94.45%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.4639 of 5 stars	4.5	2.0	0.0	4.2	2.0	1.7	0.6
CABA Cabaletta Bio	1.5368 of 5 stars	3.5	2.0	0.0	0.0	0.0	0.8	0.6
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	89.99% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	855.53% Upside
CBMG Cellular Biomedicine Group	0.00	N/A	N/A	N/A
GRTS Gritstone bio	2.50	Moderate Buy	$2.17	∞ Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRTS, TCRR, CBMG, BCRX, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.08	N/A	N/A	($2.30) per share	-3.82
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CBMG Cellular Biomedicine Group	$340K	0.00	N/A	N/A	$2.89 per share	0.00
GRTS Gritstone bio	$496K	0.00	N/A	N/A	$0.54 per share	0.00
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.55	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CBMG Cellular Biomedicine Group	-$49.98M	N/A	N/A	N/A	N/A	N/A	-144.80%	-61.68%	N/A
GRTS Gritstone bio	-$138.49M	-$1.24	N/A	N/A	N/A	-910.50%	-328.51%	-82.53%	N/A
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A

Latest GRTS, TCRR, CBMG, BCRX, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.02	N/A	N/A	N/A	$149.59 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CABA Cabaletta Bio	N/A	3.96	3.96
CBMG Cellular Biomedicine Group	N/A	0.47	0.47
GRTS Gritstone bio	1.83	2.54	2.54
TCRR TCR2 Therapeutics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CABA Cabaletta Bio	N/A
CBMG Cellular Biomedicine Group	21.98%
GRTS Gritstone bio	48.46%
TCRR TCR2 Therapeutics	64.76%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
CABA Cabaletta Bio	11.25%
CBMG Cellular Biomedicine Group	8.50%
GRTS Gritstone bio	4.61%
TCRR TCR2 Therapeutics	25.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CBMG Cellular Biomedicine Group	217	19.48 million	N/A	Optionable
GRTS Gritstone bio	190	108.57 million	111.84 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable

GRTS, TCRR, CBMG, BCRX, and CABA Headlines

Recent News About These Companies

TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment

April 17, 2024 | pharmaceutical-technology.comP

Poseida Therapeutics Inc Ordinary Shares PSTX

February 25, 2024 | morningstar.comM

DICE Therapeutics Inc.

June 20, 2023 | wsj.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1, 2023 | finance.yahoo.com

TCR2 Therapeutics Insider Trades Send a Signal

May 16, 2023 | benzinga.com

Recap: TCR2 Therapeutics Q1 Earnings

May 12, 2023 | msn.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | marketwatch.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

April 15, 2023 | finance.yahoo.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 25, 2023 | msn.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finanznachrichten.de

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finance.yahoo.com

What To Know About Jefferies's Downgrade of TCR2 Therapeutics

March 9, 2023 | msn.com

4 Analysts Have This to Say About TCR2 Therapeutics

March 9, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright

March 8, 2023 | markets.businessinsider.com

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

March 6, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout

March 6, 2023 | benzinga.com

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

March 6, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTS, TCRR, CBMG, BCRX, and CABA Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.79 +0.03 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.90 +0.11 (+1.24%)

As of 06:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cabaletta Bio NASDAQ:CABA

$1.51 +0.02 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 +0.01 (+0.66%)

As of 06:15 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time